Sandy Srinivas
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Uro-Oncology Clinic 875 Blake Wilbur Dr Clinic E Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 736-1640
- Academic Offices
Personal Information Email Tel (650) 724-8372 Tel (650) 725-2078Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Urologic Oncology
- Bladder Cancer
- Bladder Cancer - Medical Oncology
- Germ Cell Tumors
- Germ Cell Tumors - Medical Oncology
- Germ Cell Tumors - Urologic Oncology
Administrative Appointments
- Prostate Panel member, NCCN (2002 - present)
- DSMC Vice Chair, Stanford University (2002 - present)
Honors and Awards
- Oncology Clinical Fellows Teaching award, Stanford University (2009)
- Oncology Clinical Fellows Teaching award, Stanford University (2008)
- Oncology Clinical Fellows teaching award, Stanford University (2007)
- Oncology Clinical Fellows Teaching award, Stanford University (2006)
- Oncology Clinical Fellows Teaching award, Stanford University (2005)
- Oncology Clinical Fellows teaching award, Stanford University (2004)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (1997) |
| Residency: | St. Mary's Hospital - New York NY (1991) |
| Medical Education: | Madras University Medicine, India (1985) |
| Fellowship: | UCSF Medical Center CA (1994) |
| Internship: | St. Mary's Hospital - New York NY (1991) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
The Genito-Urinary Multidisciplinary tumor board at Stanford specalizes in taking care of patients with prostate cancer, renal cancer, testicular and bladder cancer. Patients are seen at different stages of their tumor. A multisdiscplinary approach is used. A variety of clinical trials are available to patients. Phase II trials using unique combination of chemotherapy agents, antiangiogenic drugs, novel agents are being explored.Co-operative group particpation through ECOG is also available
Clinical Trials
- Recruiting Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
- Recruiting Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery
- Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
- Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
- Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Publications
- A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2013; (2): 100-6
- Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013; (4): 412-9
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013; (2): 181-6
- Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol. 2013; (3): 379-85
- Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013; (1): 215-24
- Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 2012; (9): 927-35
Help